See how private equity and venture capital firms use instant CIN-based company intelligence to uncover director red flags, hidden litigations, undisclosed debt, and financial deterioration before committing capital — reducing deal screening time by 90% and catching 3x more red flags than manual research.

Private equity and venture capital firms evaluate dozens of investment opportunities every quarter. Before committing capital, investment teams must verify the target company's corporate structure, promoter background, financial health, existing debt obligations, and legal standing. Traditionally, this requires weeks of manual research across fragmented government databases, expensive third-party reports, and multiple legal opinion letters — creating deal delays and leaving blind spots that surface only after the investment is made.
Finpass Company DNA gives investment teams instant access to a comprehensive 360-degree intelligence report on any target company or LLP. By entering a CIN or LLPIN, analysts get a structured, source-verified report covering corporate identity, promoter history, financial trends, debt exposure, litigation landscape, and regulatory compliance — all in under 3 seconds.
Complete DIN-based profiling of every director and designated partner — mapping all current and past directorships, identifying directors of struck-off companies, disqualified individuals, and tracing group structures to uncover related-party risks before investment.
Multi-year revenue, profit/loss, balance sheet, and net worth data sourced directly from ROC filings — enabling investors to verify self-reported numbers, assess growth trajectory, and benchmark capital adequacy against peer companies.
Complete MCA charge register showing all secured and unsecured borrowings, charge holders, creation dates, satisfaction status, and outstanding amounts — revealing the true debt exposure that cap tables and term sheets may not disclose.
Aggregated view of active cases across High Courts, District Courts, NCLT, NCLAT, consumer forums, and arbitration tribunals — with case classification and risk severity scoring to flag material legal risks to the investment thesis.
Investment analyst enters the target company's CIN, LLPIN, or company name into the Finpass dashboard. For bulk deal pipeline screening, use the API to check multiple companies in a single batch request.
Company DNA aggregates data from 50+ sources — MCA21, ROC filings, court databases, GST Network, EPFO, and regulatory bodies — and delivers a structured intelligence report in under 3 seconds with full source attribution.
Automated algorithms scan 40+ risk signals including frequent director changes, filing delays, unsatisfied charges, pending insolvency proceedings, and financial deterioration patterns — generating an investment risk score with detailed flag explanations.
Export reports as structured PDF or JSON for deal room documentation. Set up post-investment monitoring alerts for material changes — new charges, director exits, litigation filings, or compliance lapses — on portfolio companies.
PE and VC firms using Finpass Company DNA for pre-investment due diligence have dramatically improved deal screening speed, risk identification accuracy, and overall portfolio quality.
Target company research reduced from 2-3 weeks to same-day with comprehensive automated intelligence
Hidden charges, director disqualifications, and undisclosed litigations identified that manual research missed
Reduced dependence on expensive third-party reports and external legal research for initial screening
Every data point traced to MCA, court registries, or government databases — no unverified or scraped information
"Company DNA completely changed how we screen deals. We caught a promoter with two previously struck-off companies and an active NCLT case against a group entity — none of which showed up in the pitch deck. That one catch alone saved us from a potentially devastating investment."
Join 3000+ financial institutions using Finpass to automate their lending workflows